Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 346 Neoplasms 247 Prostatic Neoplasms 198 Colorectal Neoplasms 151 Lung Neoplasms 130 Carcinoma, Non-Small-Cell Lung 108 Leukemia, Myeloid, Acute 107 Pancreatic Neoplasms 98 Multiple Myeloma 89 Glioblastoma 77 Precursor Cell Lymphoblastic Leukemia-Lymphoma 73 Brain Neoplasms 73 Head and Neck Neoplasms 72 Carcinoma, Hepatocellular 67 Squamous Cell Carcinoma of Head and Neck 65 Melanoma 62 Uterine Cervical Neoplasms 61 Ovarian Neoplasms 59 Neoplasm Metastasis 55 Rectal Neoplasms 52 Hematologic Neoplasms 50 Recurrence 48 Stomach Neoplasms 47 Glioma 46 Myelodysplastic Syndromes 45 Motor Activity 45 Triple Negative Breast Neoplasms 44 Carcinoma, Renal Cell 44 Endometrial Neoplasms 43 Sarcoma 41

Interventions

Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HER2-positive Metastatic Breast Cancer × 30 days × Clear all

NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡